Cyclic pamidronate therapy in children with osteogenesis imperfecta

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 1-2, 2010, Pages 73-80

  Salehpour, S ^a   Tavakkoli, S ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Osteogenesis imperfecta; Pamidronate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; PAMIDRONIC ACID; PARACETAMOL; PHOSPHATE; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BIOCHEMICAL COMPOSITION; BONE DENSITOMETRY; BONE GROWTH; BONE MINERALIZATION; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM URINE LEVEL; CHILD; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CLINICAL ASSESSMENT; COMMON COLD; COUGHING; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FLU LIKE SYNDROME; FRACTURE HEALING; FRACTURE NONUNION; FRACTURE REDUCTION; GROWTH RATE; HUMAN; HYPOCALCEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; ORAL PARESTHESIA; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PATIENT MOBILITY; PHOSPHATE BLOOD LEVEL; PHYSICAL MOBILITY; PRESCHOOL CHILD; RICKETS; SCHOOL CHILD; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 77950834210     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2010.23.1-2.73     Document Type: Article

References (42)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-116.
2. 2. Andersen PE Jr, Hauge M. Osteogenesis imperfecta: a genetic, radiological, and epidemiological study. Clin Genet 198936: 250-255. (Pubitemid 19248596)
3. Glorieux FH, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-1658.
4. 4. Glorieux FH, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-38. (Pubitemid 33150994)
5. Francis MJO, Bauze RJ, Smith R. Osteogenesis imperfecta: a new classification. Birth Defects Orig Artie Ser 1975; 11: 99-102.
6. Glorieux FH, Travers R, Chabot G, Lanoue G. Bone histomorphometric analysis in osteogenesis imperfecta. J Bone Miner Res 1994; 9: 226-227.
7. 7. Pedersen U, Charles P, Hansen HH, Elbrond O. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop Scand 1985; 56:260-264. (Pubitemid 16246543)
8. Cattell HS, Clayton B. Failure of anabolic steroids in the therapy of osteogenesis imperfecta: a clinical, metabolic, and biochemical study. J Bone Joint Surg Am 1968; 50: 123-141.
9. Albright JA, Grunt JA. Studies of patients with osteogenesis imperfecta. J Bone Joint Surg Am 1971; 53: 1415-1425.
10. Castells S. New approaches to treatment of osteogenesis imperfecta. Clin Orthop 1973; 93: 239-249.
11. Esposito P, Turman K, Scherl S, et al. Percutaneous surgical treatment of multiple lower extremity deformities in children with osteogenesis imperfecta. In: Proceedings of 2006 Annual Meeting of the Pediatric Orthopedic Society of North America. Rosemont, IL: Pediatric Orthopedic Society of North America; 2006; 103.
12. Plotkin H. Two questions about osteogenesis imperfecta. J Pediatr Orthop 2006; 26: 148-149.
13. 13. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclical Pamidronate therapy in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952. (Pubitemid 28455096)
14. Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M. Pamidronate treatment of children with moderate-tosevere osteogenesis imperfecta: a note of caution. Horm Res 2009; 71: 38-44.
15. Russell RGG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119: 150-162.
16. Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 2007; 119: 163-165.
17. Hickey J, Lemons D, Waber P, Seikaly MG. Bisphosphonate use in children with bone disease. J Am Acad Orthop Surg 2006; 14: 638-644.
18. 18. Rauch F, Travers R, Glorieux FH. Pamidronate in v children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91: 511-516. (Pubitemid 43236917)
19. Huang R, Ambrose CG, Sullivan E, Haynes RJ. Functional significance of bone density measurements in children with osteogenesis imperfecta. J Bone Miner Res 2005; 20; 977-986.
20. Ward L, Tricco AC, Phuong P, Cranney A. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. J Clin Endocrinol Metab 2000;85:1846-1850.
21. 21. Vyskočil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005; 72:416-423. (Pubitemid 41415831)
22. Unal E, Abaci A, Bober E, Buyukgebiz A. Oral alendronate in osteogenesis imperfecta. Indian Pediatr 2005; 17: 1158-1160.
23. Plotkin H, Lutz R. Osteoporosis in pediatrics. In: Deng HW, Liu Y, eds. Current Topics in Osteoporosis. Singapore: World Scientific, 2005; 362-414.
24. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop 1981; 159: 111-122.
25. 25. Sykes B, Ogilvie D, Wordsworth P, et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COLIAI and COL1A2. Am J Hum Genet 1990; 46:293-307. (Pubitemid 20077598)
26. 26. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204-207. (Pubitemid 13138172)
27. 27. Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with Osteogenesis imperfecta. J Bone Miner Res 1994; 9: 993-997. (Pubitemid 24191786)
28. Fleisch H. Bisphosphonates: mechanism of action. Endocr Rev 1998; 19: 80-100.
29. Meunier P, Vignot E. Therapeutic strategy in Paget's disease of bone. Bone 1995; 17 (Suppl): 489-491.
30. 30. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997; 12: 1746-1752. (Pubitemid 27422377)
31. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-774.
32. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997; 156: 792-794.
33. 33. Buckmaster A, Rodda C, Cowell C, Ogle G, Dorney S. The use of Pamidronate in PTHrP associated hypercalcaemia in infancy. J Pediatr Endocrinol Metab 1997; 10: 301-304. (Pubitemid 27254987)
34. 34. Plotkin H, Rauch F, Bishop NJ, Montpetit K, RuckGibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-1850. (Pubitemid 32269287)
35. 35. Plotkin H, Nunez M, Alvarez Filgueira ML, Zanchetta JR. Lumbar spine bone density in Argentine children. Calcif Tissue Int 1996; 58: 144-149. (Pubitemid 26080997)
36. 36. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 1994; 70: 331-334. (Pubitemid 24174750)
37. 37. Reinus WR, McAlister WH, Schránek F, Chines A, Whyte MP. Differing lumbar vertebral mineralization rates in ambulatory pediatric patients with osteogenesis imperfecta. Calcif Tissue Int 1998; 62: 17-20. (Pubitemid 28018669)
38. Frost HM. Vital biomechanics: proposed general concepts for skeletal adaptations to mechanical usage. Calcif Tissue Int 1988; 42: 145-156.
39. Cheung MS, Glorieux FH, Rauch F. Intravenous Pamidronate in osteogenesis imperfecta type VII. Calcif Tissue Int 2009; 84: 203-209.
40. 40. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309-318. (Pubitemid 39108843)
41. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 1992; 50: 36-41.
42. 42. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-283. (Pubitemid 27357867)